Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21476667 | 0.87 | CTSA (0.43) | CYP11B1CYP11B2CNR2CTSAKCNH2 | |
| SCHEMBL21475993 | 0.81 | FFAR1 (0.48) | CYP11B1CYP11B2CNR2CCNCCDK8 | |
| SCHEMBL21475921 | 0.76 | CYP11B1 (0.42) | CYP11B1CYP11B2CNR2CCNCCDK8 | |
| SCHEMBL3745313 | 0.72 | CYP11B2 (0.48) | CYP11B1CYP11B2CNR2CTSACCNC | |
| SCHEMBL21480470 | 0.71 | HTR1A (0.50) | CNR2CTSAGRIN2BFFAR1 | |
| SCHEMBL3931688 | 0.70 | CYP11B1 (0.48) | CYP11B1CYP11B2CCNCCDK8 | |
| SCHEMBL22364153 | 0.69 | HDAC1 (0.45) | CYP11B1CYP11B2CNR2CCNCCDK8 | |
| SCHEMBL1532963 | 0.69 | HSP90AB1 (0.47) | CYP11B1CYP11B2CCNCCDK8 | |
| SCHEMBL2965106 | 0.68 | MTNR1A (0.61) | — | |
| SCHEMBL1746857 | 0.68 | FFAR1 (0.65) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |